- Scrip
- >>Business
- >>Deals
- >>Deal Watch
Asia Deal Watch: invoX Builds Novel Pipeline Through $161m F-star Acquisition
Dr. Reddy's Commits Up To $50m For Injectables From Eton
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Wholly-owned Sino Biopharmaceutical Limited subsidiary invoX Pharma announced on 23 June it entered into a definitive agreement to acquire Nasdaq-listed F-star Therapeutics, Inc
